ClinicalTrials.gg
Status unknownNCT03438955Updated Feb 22, 2018

Phase I Drug-drug Interaction of Omega-3 and Atorvastatin

A Phase 1 interventional study of Omacor and Pritor in Hyperlipidemia, Hypertriglyceridemia, sponsored by DongKoo Bio & Pharma. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-22.

Primary conditionHypertriglyceridemiaRegistry: HyperlipidemiasReclassifiedWhy we changed it
Registry
Hyperlipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertriglyceridemia
Why
  1. The study's listed conditions name Hypertriglyceridemia, a narrower term within Hyperlipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by DongKoo Bio & Pharma · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
19 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing omacor in Hypertriglyceridemia — none open to participants now, none under way, none of them phase 3. Omacor · Hypertriglyceridemia.

Planned enrollment
11th of 21
48 · median 48
Started
2018
the only one that year
Phase 1
4 of 21
none open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
DongKoo Bio & Pharma

Among the 21 studies testing omacor in Hypertriglyceridemia, this one is the 11th largest by planned enrollment, is the only one that started in 2018, is one of 4 in phase 1, and was the 21st registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

None of the 21 studies testing omacor in Hypertriglyceridemia is open now. The open studies under Hypertriglyceridemia, anywhere →

About omacor

Omacor: first FDA approval 2004 (LOVAZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 19 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing omacor in Hypertriglyceridemia as a file.
02

Study summary

This study evaluates the safety and pharmacokinetic drug-drug interactions of omega-3 and atorvastatin in healthy male volunteers. Half of the participants will receive omega-3 for 16 days to be steady state of omega-3 and followed by omega-3 and atorvastatin in combination for 7 days. The other half will receive Atorvastatin for 7 days to be steady state of Atorvastatin, and followed by Atorvastatin and Omega-3 in combination for 16 days.

03

Conditions studied

  • Hyperlipidemia, Hypertriglyceridemia

Browse trials for

04

In context

Hypertriglyceridemia Reclassified

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

This study's planned enrollment of 48 is below the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.

Browse Hypertriglyceridemia studies →

Lead sponsor

This is the only study on the registry with DongKoo Bio & Pharma as lead sponsor.

Compared within Hypertriglyceridemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • 50kg or less of body weight and of 18 \~ 30kg/m²
  • No congenital or chronic disease requiring treatment, and no pathological symptoms or findings as a result of medical examination
  • Eligible for the clinical trial as a result of a clinical laboratory test, 12-lead , V/S test at the screening

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cohort A

    Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.

    Drug: Omacor · Drug: Omacor + Pritor

  • Experimental
    Cohort B

    Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.

    Drug: Pritor · Drug: Pritor + Omacor

Interventions

  • DrugOmacor

    Omacor soft capsule 4000mg for 16days

  • DrugPritor

    Pritor tablet 40mg for 7days

  • DrugOmacor + Pritor

    Drug pages: Omacor · Telmisartan

    Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days

  • DrugPritor + Omacor

    Drug pages: Telmisartan · Omacor

    Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas

07

What researchers measure

Primary outcomes

  1. Cohort A

    Area under curve(0-t) of EPA total lipid and Docosahexaenoic acid total lipid AUC t,ss and C max, ss of Atorvastatin

    Time frame: Day 1 -20hours, -16hours, -12hours, 0hours, Day 13, 14, 15 0hours, Day 16 0, 1, 2, 3, 4, 6, 8, 12, 24hours, Day 23 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24hours

  2. Cohort B

    Area under curve(0-t) of Atorvastatin

    Time frame: Day 1 0hours, Day 5, 6 0hours, Day 7 0, 0.25 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12 ,24hours, Day 23 0, 0.25, 0.5, 0.75, 1, 1.25, 2, 3, 4, 6, 8, 12, 24hours

08

Study locations

1 of 1 sites recruiting
  • Dong-A National University Hospital
    Busan, 49201, Korea, Republic of
    Recruiting
    • Min Kyu Park · Contact
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2018 (actual). Primary completion is estimated for Jul 2018, 5 months after the start.

Of 15 phase 1 interventional studies under Hypertriglyceridemia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 28. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2018
First posted
Feb 20, 2018
StartActual
Feb 1, 2018
Primary completionEst.
Jul 31, 2018
CompletionEst.
Aug 31, 2018
Last update
Feb 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03438955
Lead sponsor
DongKoo Bio & Pharma
Responsible party
Sponsor
First posted
Feb 20, 2018
Start date
Feb 1, 2018
Primary completion
Jul 31, 2018 (estimated)
Completion
Aug 31, 2018 (estimated)
Last update
Feb 22, 2018

Study contacts

Min Kyu Park, MD
Contact
minkpark@dau.ac.kr
+82 51 240 5180
Min Kyu Park, MD
principal investigator · Dong-A National Univ. Hos.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omacor · Telmisartan

Start the discussion